MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation

NASDAQ:MDXG • US6024961012

4.51 USD
+0.01 (+0.22%)
At close: Mar 9, 2026
4.51 USD
0 (0%)
After Hours: 3/9/2026, 8:19:55 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, MDXG scores 6 out of 10 in our fundamental rating. MDXG was compared to 519 industry peers in the Biotechnology industry. MDXG has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MDXG has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. MDXG Profitability Analysis

1.1 Basic Checks

  • In the past year MDXG was profitable.
  • In the past year MDXG had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
  • In multiple years MDXG reported negative operating cash flow during the last 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • With an excellent Return On Assets value of 14.18%, MDXG belongs to the best of the industry, outperforming 94.99% of the companies in the same industry.
  • With an excellent Return On Equity value of 18.94%, MDXG belongs to the best of the industry, outperforming 95.57% of the companies in the same industry.
  • The Return On Invested Capital of MDXG (16.82%) is better than 96.92% of its industry peers.
  • MDXG had an Average Return On Invested Capital over the past 3 years of 16.63%. This is below the industry average of 19.44%.
  • The last Return On Invested Capital (16.82%) for MDXG is above the 3 year average (16.63%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROIC 16.82%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • MDXG's Profit Margin of 11.60% is amongst the best of the industry. MDXG outperforms 91.33% of its industry peers.
  • MDXG has a Operating Margin of 15.26%. This is amongst the best in the industry. MDXG outperforms 92.49% of its industry peers.
  • MDXG's Operating Margin has improved in the last couple of years.
  • The Gross Margin of MDXG (82.56%) is better than 85.74% of its industry peers.
  • In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
Industry RankSector Rank
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MDXG Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
  • The number of shares outstanding for MDXG has been increased compared to 1 year ago.
  • The number of shares outstanding for MDXG has been increased compared to 5 years ago.
  • MDXG has a better debt/assets ratio than last year.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MDXG has an Altman-Z score of 7.07. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
  • MDXG has a Altman-Z score of 7.07. This is in the better half of the industry: MDXG outperforms 76.88% of its industry peers.
  • MDXG has a debt to FCF ratio of 0.25. This is a very positive value and a sign of high solvency as it would only need 0.25 years to pay back of all of its debts.
  • MDXG has a better Debt to FCF ratio (0.25) than 95.95% of its industry peers.
  • MDXG has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • MDXG has a Debt to Equity ratio (0.06) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Altman-Z 7.07
ROIC/WACC1.94
WACC8.69%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 4.32 indicates that MDXG has no problem at all paying its short term obligations.
  • MDXG's Current ratio of 4.32 is in line compared to the rest of the industry. MDXG outperforms 50.10% of its industry peers.
  • MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • MDXG has a Quick ratio (3.92) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 3.92
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDXG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.38% over the past year.
  • The Revenue has grown by 19.99% in the past year. This is quite good.
  • MDXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.02% yearly.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%

3.2 Future

  • MDXG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.82% yearly.
  • MDXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.92% yearly.
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-14.71%
Revenue Next 2Y-1.76%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. MDXG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.00, which indicates a very decent valuation of MDXG.
  • MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.92% of the companies in the same industry.
  • MDXG's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
  • Based on the Price/Forward Earnings ratio of 39.01, the valuation of MDXG can be described as expensive.
  • Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 91.91% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.65. MDXG is valued rather expensively when compared to this.
Industry RankSector Rank
PE 11
Fwd PE 39.01
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 98.07% of the companies in the same industry.
  • 98.07% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.18
EV/EBITDA 6.61
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • MDXG has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as MDXG's earnings are expected to decrease with -7.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDXG Dividend Analysis

5.1 Amount

  • MDXG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXG Fundamentals: All Metrics, Ratios and Statistics

MIMEDX GROUP INC

NASDAQ:MDXG (3/9/2026, 8:19:55 PM)

After market: 4.51 0 (0%)

4.51

+0.01 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners73.14%
Inst Owner Change0.19%
Ins Owners1.74%
Ins Owner Change1.03%
Market Cap670.05M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (118.63%)
Short Float %5%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)-7.05%
PT rev (3m)-20.76%
EPS NQ rev (1m)-191.65%
EPS NQ rev (3m)-191.65%
EPS NY rev (1m)3.03%
EPS NY rev (3m)-53.74%
Revenue NQ rev (1m)-26.88%
Revenue NQ rev (3m)-26.88%
Revenue NY rev (1m)-12.3%
Revenue NY rev (3m)-16.5%
Valuation
Industry RankSector Rank
PE 11
Fwd PE 39.01
P/S 1.6
P/FCF 9.18
P/OCF 9.05
P/B 2.61
P/tB 3.01
EV/EBITDA 6.61
EPS(TTM)0.41
EY9.09%
EPS(NY)0.12
Fwd EY2.56%
FCF(TTM)0.49
FCFY10.89%
OCF(TTM)0.5
OCFY11.04%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99
Profitability
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROCE 22.95%
ROIC 16.82%
ROICexc 41.72%
ROICexgc 59.54%
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
FCFM 17.43%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Debt/EBITDA 0.21
Cap/Depr 6.94%
Cap/Sales 0.25%
Interest Coverage 51.27
Cash Conversion 93.95%
Profit Quality 150.21%
Current Ratio 4.32
Quick Ratio 3.92
Altman-Z 7.07
F-Score5
WACC8.69%
ROIC/WACC1.94
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-14.71%
Revenue Next 2Y-1.76%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-15.56%
EBIT Next 3Y15.13%
EBIT Next 5Y12.86%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.


What is the profitability of MDXG stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.


What is the financial health of MIMEDX GROUP INC (MDXG) stock?

The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.


What is the earnings growth outlook for MIMEDX GROUP INC?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -71.81% in the next year.